demenza

Alzheimer’s Drug Discovery Foundation – Prevention pipeline

Through its Prevention beyond the pipeline Program,The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Duration: Multi-year Average award: Up to $3,000,000 for clinical trials based on stage […]

Alzheimer’s Drug Discovery Foundation – Prevention pipeline Leggi tutto »

JPND Call for Proposals:”Mechanisms and measurement of disease progression in theearly phase of neurodegenerative diseases”

The call aims to improve the understanding of disease mechanisms and advance the measurability of disease progression at early and presymptomatic stages of neurodegenerative diseases. Proposals submitted under this call may include, but are not limited to, the following types of research: Unraveling the influence of molecular, physiological, psychological, and social factors and pathways on disease progression as well

JPND Call for Proposals:”Mechanisms and measurement of disease progression in theearly phase of neurodegenerative diseases” Leggi tutto »

Alzheimer’s Drug Discovery Foundation – Neuroimaging and CSF Biomarker development program

Given the pathological heterogeneity of Alzheimer’s disease and related dementias, new biomarkers are needed to more accurately characterize specific underlying pathophysiology. This RFP seeks to support the development of CSF and neuroimaging biomarkers for multiple contexts of use (see below) that include but are not limited to: Demonstrate target engagement for novel therapeutics Biomarkers that

Alzheimer’s Drug Discovery Foundation – Neuroimaging and CSF Biomarker development program Leggi tutto »

Alzheimer’s Drug Discovery Foundation – Program to Accelerate Clinical Trials (PACT)

The PACT RFP supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered. This funding opportunity prioritizes diverse drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for

Alzheimer’s Drug Discovery Foundation – Program to Accelerate Clinical Trials (PACT) Leggi tutto »

Alzheimer’s Drug Discovery Foundation – Drug Development Program

Through its Drug Development Program the ADDF seeks to support in vivo preclinical studies that advance lead molecules developed for Alzheimer’s disease and related dementias to IND-enabling studies. The proposed studies should be structured to deliver a compound with strong potential for clinical and commercial application. Drug mechanisms or modes of action: Novel drug mechanisms and

Alzheimer’s Drug Discovery Foundation – Drug Development Program Leggi tutto »

Alzheimer’s Drug Discovery Foundation – Program to Accelerate Clinical Trials (PACT)

L’obiettivo del bando è l’aumento del numero di trattamenti nuovi per la malattia di Alzheimer, le demenze correlate e l’invecchiamento cognitivo (studi clinici pilota basati su biomarker per i test di sicurezza di Alzheimer, così come i test di sicurezza di fase 1) Le proposte progettuali possono avere una durata variabile e il finanziamento massimo è

Alzheimer’s Drug Discovery Foundation – Program to Accelerate Clinical Trials (PACT) Leggi tutto »

Alzheimer’s Drug Discovery Foundation – Prevention beyond the pipeline

Through its Prevention beyond the pipeline Program, the ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Duration: One year for epidemiological analyses Varies (multi-year) for clinical trials Average award: $50,000-$100,000 for epidemiological analyses

Alzheimer’s Drug Discovery Foundation – Prevention beyond the pipeline Leggi tutto »

Alzheimer’s Drug Discovery Foundation – Neuroimaging and CSF Biomarker development program

Given the pathological heterogeneity of Alzheimer’s disease and related dementias, new biomarkers are needed to more accurately characterize specific underlying pathophysiology. This RFP seeks to support the development of CSF and neuroimaging biomarkers for multiple contexts of use (see below) that include but are not limited to: Clearly demonstrate target engagement for novel therapeutics The

Alzheimer’s Drug Discovery Foundation – Neuroimaging and CSF Biomarker development program Leggi tutto »

Alzheimer’s Drug Discovery Foundation – Drug Development Program

Through its Drug Development Program the ADDF seeks to support develop therapeutics for Alzheimr’s disease and related dementias. Thsi program focuses on building preclinical evidence in animal models and on adavncing leas molecules to the clincal candidate selection stage. The propose studies shoudl have a high probability or reaching IND-enabling stuides within two years. Current

Alzheimer’s Drug Discovery Foundation – Drug Development Program Leggi tutto »

Alzheimer’s Research UK – Target Validation Pathfinder Grant

The Target Validation Pathfinder Grant scheme provides funds for small, translational research projects that show potential for an application to the Dementia Consortium or collaboration with the ARUK Drug Discovery Alliance. The lead applicant and point of contact must be based in an academic/research institution, either in the UK or abroad. Co-applicants from small and medium enterprises

Alzheimer’s Research UK – Target Validation Pathfinder Grant Leggi tutto »

Torna in alto